Search Results
Your search for ,dUe matches 5408 pages
Showing 4901 - 4950Preclinical Study Reveals Why Chemotherapy May Be Compromised in Patients With Pancreatic Cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many patients with pancreatic cancer and perhaps point to new approaches to treatment, including enhancing gemcitabine's ability to stop tumor growth. The MD...
FDA Approves Cobimetinib in Combination With Vemurafenib for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) approved cobimetinib (Cotellic) to be used in combination with vemurafenib (Zelboraf) to treat metastatic or unresectable melanoma, with the BRAF V600E or V600K mutation. “As we continue to advance our knowledge of tumor biology, we have...
Improved Outcomes With Modified Docetaxel, Cisplatin, and 5-FU vs Standard Regimen Plus Growth Factor Support in Metastatic Gastric Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Shah et al in the U.S. Gastric Cancer Consortium found that a modified regimen of docetaxel, cisplatin, and fluorouracil (5-FU) (mDCF) improved toxicity and survival vs a standard DCF regimen plus growth factor support as first-line...
No Difference in Overall Survival, Poorer Relapse-Free Survival With Adjuvant Intermittent vs High-Dose Interferon Alfa-2b in Stage III Melanoma
The final analysis of a European Dermatologic Cooperative Oncology Group phase III trial, reported in the Journal of Clinical Oncology by Mohr et al, showed that adjuvant intermittent vs standard high-dose intravenous interferon alfa-2b was associated with no difference in overall survival but...
No Reduction in Recurrent Colorectal Adenomas With Vitamin D and Calcium Supplementation
In a trial reported in The New England Journal of Medicine, Baron et al found that daily vitamin D and calcium supplementation did not reduce recurrence of colorectal adenomas in patients with recently diagnosed adenomas and no known polyps remaining after complete colonoscopy. Study Details In...
No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer
In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...
Exercise Could Provide a Margin of Safety for Women Who Want to Delay Preventive Mastectomy
Regular physical activity could play a role in helping women at high-risk of breast cancer delay the need for drastic preventive measures such as prophylactic mastectomy, according to new research led by the Perelman School of Medicine at the University of Pennsylvania. Results of the WISER Sister...
FDA Approves Adjuvant Ipilimumab to Reduce the Risk of Melanoma Returning After Surgery
The U.S. Food and Drug Administration has expanded the approved use of ipilimumab (Yervoy) to include a new use as adjuvant therapy for patients who have cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm and have undergone complete resection, including total...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
Good Outcome With Neoadjuvant Chemoradiation and Local Excision in Clinical T2,N0 Distal Rectal Cancer
In a multi-institutional phase II trial (ACOSOG Z6041) reported in The Lancet Oncology, Garcia-Aguilar et al found that neoadjuvant chemoradiotherapy and local excision was associated with an acceptable disease-free survival rate, albeit not so high as anticipated, in patients with clinical stage...
ASTRO 2015: Involved-Field Irradiation for Locally Advanced Esophageal Cancer Reduces Toxicity Without Increasing Locoregional Lymph Node Recurrence
For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy that targets only the involved lymph node regions results in less toxicity without causing a statistically significant difference in locoregional lymph node recurrence, distant failure, and...
FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration today approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National...
ASTRO 2015: Frequent Post-Treatment Follow-up by Advance Practice Nurses Improves Care for Patients With High-Risk Head and Neck Cancer
For high-risk patients who receive chemoradiotherapy for head and neck cancer, frequent follow-up appointments conducted by advance practice nurses (APNs) in a clinical outpatient setting allowed for more intensive symptom management, resulting in fewer post-treatment emergency room visits and...
How Physicians Communicate With Parents May Discourage HPV Vaccination of Adolescents
A nationwide online survey of 776 pediatricians and family physicians assessing the quality of their human papillomavirus (HPV) vaccine recommendations to parents has found that a sizable minority of physicians—27%—said they do not strongly endorse HPV vaccination, and 26% and 39%...
ASTRO 2015: Accelerated Partial-Breast Irradiation With Brachytherapy After Breast-Conserving Surgery Is as Effective as Whole-Breast Irradiation
For some early-stage breast cancer patients, accelerated partial-breast irradiation using multicatheter brachytherapy following breast-conserving surgery may be an excellent treatment option, as it has now been proven to be as effective as the current standard treatment—whole-breast...
Anticancer Effects of Drugs Overestimated by as Much as 45% in Preclinical Animal Studies
Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to new a study from McGill University in Montreal. The findings, published by Henderson et al in eLife, highlight the importance of ensuring that other...
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer
Results of the phase III AHT trial reported in the Journal of Clinical Oncology by Eeles et al suggest that adjuvant hormonal therapy may improve survival in women with epithelial ovarian cancer. The trial, started in 1990, was stopped early due to low recruitment. Study Details In the open-label ...
FDA Approves Use of Nivolumab in Advanced Nonsquamous Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved nivolumab (Opdivo) to treat patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. Nivolumab is a monoclonal antibody that that blocks the...
Therapeutic HPV-16/18 Vaccine Produces Regression of Cervical Intraepithelial Neoplasia Grade 2/3 in Phase II Trial
In a phase IIb trial reported in The Lancet, Trimble et al found that a therapeutic synthetic vaccine (VGX-3100) targeting human papillomavirus (HPV) 16 and 18 E6 and E7 proteins increased the frequency of regression of HPV-16/18–related cervical intraepithelial neoplasia grade 2/3 vs...
Disparities in Outcomes for Children With Retinoblastoma May Suggest Unequal Access to Primary Care
Disparities in outcomes for children with retinoblastoma suggest unequal access to primary care, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center reported in a study published by Truong et al in JAMA Pediatrics. Although virtually all the children in the study...
ASCO Endorses CHEST Guideline on Treatment of Small Cell Lung Cancer
As reported in the Journal of Clinical Oncology, ASCO has endorsed the current American College of Chest Physicians (CHEST) guideline on treatment of small cell lung cancer, released in 2013. After review of evidence from an updated literature search covering 2011 to March 2015, an ASCO...
Phase IIb Trial Shows Improved Progression-Free Survival With First-Line Aldoxorubicin vs Doxorubicin in Advanced Soft-Tissue Sarcoma
In a randomized phase IIb trial reported in JAMA Oncology, Chawla et al found that aldoxorubicin—a novel albumin-binding prodrug of doxorubicin—produced longer progression-free survival than doxorubicin as first-line treatment for metastatic or locally advanced unresectable soft-tissue...
Postprostatectomy Radiation Therapy Yields Low Toxicity and Favorable Patient-Reported Quality of Life
A prospective study of guideline-based, postoperative, image-guided intensity-modulated radiation therapy in patients with prostate cancer found low toxicity profiles and favorable patient-reported quality of life following treatment, with researchers concluding that toxicity and health-related...
ECC 2015: Pembrolizumab in Patients With Advanced Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Trial
Pembrolizumab (Keytruda), an anti–PD-1 therapy, may be effective as monotherapy in patients with advanced unresectable nasopharyngeal carcinoma whose tumors express programmed cell death-ligand 1 (PD-L1). Data from a phase Ib study, KEYNOTE-028, showed an overall response rate of 22.2% in 27...
ECC 2015: Treatment of Elderly Patients With Breast Cancer Varies Throughout Europe
First results from the largest international comparison of the treatment of elderly patients with breast cancer have shown substantial differences in the use of surgery, hormone therapy, and chemotherapy among European countries. The European Registration of Cancer Care (EURECCA) study compared the ...
Study Finds Cancer Is Increasingly Common in Patients With HIV, Necessitating Targeted Cancer Prevention Efforts
The effectiveness of antiretroviral therapy in the treatment of patients with human immunodeficiency virus (HIV) has prolonged lives and resulted in cancer becoming increasingly common in this population, with a higher burden than the general population due to impaired immune function, including...
ECC 2015: Children Exposed to Prenatal Cancer Treatment Show Normal Mental Processes and Heart Function
In a special session on cancer in pregnancy at the 2015 European Cancer Congress (Abstract 3205), Frédéric Amant, MD, PhD, said that new results from a study of 129 children, aged 1–3, born after prenatal exposure to cancer treatment, showed normal development of their...
ECC 2015: Discovery of Differences Between Tumors of Younger and Older Patients With Colorectal Cancer May Lead to Better Treatments
Colorectal cancer is on the rise among younger patients. Although some of the younger-onset cases can be explained by hereditary factors, the majority arise spontaneously. Researchers have now found that tumors in younger patients with colorectal cancer may be molecularly distinct from those of...
Study Finds No Disease-Free Survival Improvement With Adjuvant Erlotinib in EGFR-Expressing NSCLC
In the phase III RADIANT trial reported in the Journal of Clinical Oncology, Kelly et al found no disease-free survival improvement with adjuvant erlotinib (Tarceva) vs placebo in patients with EGFR-expressing stage IB to IIIA non–small cell lung cancer (NSCLC). However, there was evidence of ...
ECC 2015: EUROCARE Results Show Large Variations in Survival Among European Countries
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least 5 years after diagnosis, there are large variations among countries, which are particularly significant in cancers of the blood. Milena Sant, MD, from the...
ECC 2015: Cabozantinib Improves Survival in Patients With Advanced Kidney Cancer
Patients with advanced kidney cancer lived for nearly twice as long without their disease progressing if they were treated with cabozantinib (Cometriq), a drug that inhibits the action of tyrosine kinases. Toni Choueiri, MD, presented the research (Abstract 4LBA) at the Presidential Session of the...
Study Finds Improving Cervical Cancer Screening Practice May Generate Health Gains With Nominal Increases in Cost
Cytology-based screening has led to substantial declines in cervical cancer incidence and mortality since it was introduced in the 1940s. A population-based, cost-effective analysis investigating the benefits, costs, and cost-effectiveness of current cervical cancer screening practice, however, has ...
FDA Approves New Oral Medication for the Treatment of Refractory Metastatic Colorectal Cancer
The U.S. Food and Drug Administration today approved trifluridine/tipiracil (Lonsurf) for patients with metastatic colorectal cancer who have been previously treated with chemotherapy and biologic therapy and are no longer responding to treatment. The new agent is an oral combination of...
Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Conventional Chemotherapy in Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in the Journal of Clinical Oncology, Demetri et al found that treatment with trabectedin significantly improved progression-free survival vs dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior conventional chemotherapy. Interim analysis of...
Breast Cancer Symposium: Recurrence Rates for Ductal Carcinoma in Situ Treated Between 1978–2010
A new retrospective analysis explored local recurrence rates for women with ductal carcinoma in situ (DCIS) treated between 1978 and 2010. In the research (Abstract 32) by Van Zee et al, to be presented September 25 at the 2015 Breast Cancer Symposium, in San Francisco, investigators evaluated a...
Antifungal Agent Increases Risk of Cutaneous Squamous Cell Carcinoma in Some Lung Transplant Recipients
Voriconazole, commonly used to prevent and treat fungal infections in lung transplant recipients, significantly increases the risk for cutaneous squamous cell carcinoma in this population, according to a new study by University of California San Francisco researchers. The team recommends physicians ...
Study Finds CD38-Targeted Antibody Daratumumab Active in Relapsed Multiple Myeloma
In a phase I/II trial reported in The New England Journal of Medicine, Lokhorst et al found that the CD38-targeting human IgG1κ monoclonal antibody daratumumab had an acceptable safety profile and produced durable responses in relapsed multiple myeloma. Study Details In the dose-escalation...
Long-Term Remissions Reported in CLL Personalized Cell Therapy Trial
In the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL), 8 of 14 patients responded to the therapy, with some complete remissions continuing past 4.5 years. These results, published by Porter et al in Science Translational...
Study Explores Link Between Allele Expression and Risk of Graft-vs-Host Disease in Transplant Recipients
In a study reported in The New England Journal of Medicine, Petersdorf et al found a greater risk of acute graft-vs-host disease among hematopoietic cell transplant recipients with the high-expression rs9277534G allele linked to mismatched HLA-DPB1 who received transplants from donors with the...
BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...
Synchronous vs Sequential Tumor Resection in Patients With Advanced Colorectal Cancer
About 20% of patients with colorectal cancer have cancers that have metastasized beyond the colon at the time of their diagnosis, with the liver being the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to...
Study Explores Link Between Breast Cancer Recurrence Score and Chemotherapy Use
A genetic test that helps predict whether some women’s breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine. The study found that low-risk patients who had the test appeared to opt for more treatment, and high-risk patients who were...
WCLC: New Study Reveals Genomic Architecture of EGFR Mutations in Lung Cancer
Epidermal growth factor receptor (EGFR) mutations are one of the most common driver oncogenes in lung cancer, typified by high response rates when treated with tyrosine kinase inhibitors and median progression-free survival of 10 months, commonly due to emergence of T790M. The genomic...
WCLC: Impact of Time to Drug Approval on Potential Years of Life Lost
Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the United States and 260 life-years worldwide, according to research (Abstract ORAL12.05) presented on September 7 at the 16th World Conference on Lung Cancer hosted by the International Association of the...
Phase II Trial Shows Greater Activity With Lenalidomide/Rituximab vs Lenalidomide in Recurrent Follicular Lymphoma
In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...
Activity of Colony-Stimulating Factor-1 Receptor Kinase Inhibitor in Tenosynovial Giant Cell Tumors
In a phase I study reported in The New England Journal of Medicine, Tap et al found that a newly developed inhibitor of colony-stimulating factor-1 receptor (CSF1R) kinase showed activity in tenosynovial giant cell tumors. CSF1 gene expression is elevated in most such tumors. The structure of the...
Report of Secondary Outcomes in NSABP B-40 Indicates Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer
The phase III NSABP B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early HER2-negative breast cancer. In a report of secondary outcomes in The...
Malaria-Causing Parasite May Contribute to Development of Burkitt Lymphoma
In an equatorial African region known as the “lymphoma belt,” children are ten times more likely than in other parts of the world to develop Burkitt lymphoma. This area is also plagued by high rates of malaria, and scientists have spent the past 50 years trying to understand how the two ...
Patients With Breast Cancer Over Age 80 Less Likely to Benefit From Chemotherapy Alone Than Younger Patients
Chemotherapy prolongs life for older adults with most types of cancer, but for women with breast cancer over age 80, the chances of survival with chemotherapy alone are significantly lower than in younger patients, according to a study led by researchers from the University of Texas...
Involved-Field Radiotherapy May Be Best Option for Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
As reported by Eichenauer and colleagues in the Journal of Clinical Oncology, an analysis of long-term outcomes suggests that involved-field radiotherapy may be the best treatment option in patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma. Study Details The study involved...
